ORIC

+ Watchlist + Portfolio

Oric Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $14.65
52-Week Range: $7.23 – $14.93
Market Cap: $1.44B
P/E (TTM): —
EPS (TTM): -1.30
Dividend Yield: —

Advanced Metrics

Price/Book: 3.77
PEG Ratio: —
Return on Equity: -39.80%
Return on Assets: -25.97%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 13.19
Debt/Equity: 0.02
Total Debt: $6.00M
Free Cash Flow: $-68.83M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.18B

ORIC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$61.68M	$85.17M	$114.07M	$109.82M
Selling, General & Admin	$25.09M	$25.61M	$28.82M	$33.19M
Operating Expenses	$86.77M	$110.78M	$142.90M	$143.00M
Operating Income	-$86.77M	-$110.78M	-$142.90M	-$143.00M
EBITDA	-$85.80M	-$109.75M	-$141.79M	-$141.78M
Pretax Income	-$89.12M	-$100.70M	-$127.85M	-$129.47M
Net Income	-$89.12M	-$100.70M	-$127.85M	-$129.47M
Diluted EPS	-2.25	-1.96	-1.83	-1.47
Diluted Shares	39.66M	51.45M	69.73M	87.79M

ORIC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$66.84M	$23.38M	$59.41M	$45.67M
Current Assets	$210.46M	$212.60M	$262.25M	$288.47M
Total Assets	$247.18M	$252.01M	$274.14M	$408.89M
Current Liabilities	$15.39M	$20.46M	$24.85M	$20.42M
Total Debt	$2.66M	$2.75M	$3.18M	$3.33M
Total Liabilities	$24.83M	$27.92M	$31.02M	$24.53M
Retained Earnings	-$334.23M	-$434.93M	-$562.77M	-$692.24M
Shareholders' Equity	$222.35M	$224.09M	$243.12M	$384.36M
Working Capital	$195.07M	$192.14M	$237.40M	$268.05M

ORIC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$75.14M	-$85.69M	-$112.66M	-$110.97M
Capital Expenditure	-$2.08M	-$849.00K	-$1.19M	-$712.00K
Free Cash Flow	-$77.22M	-$86.54M	-$113.85M	-$111.68M
Depreciation & Amortisation	$966.00K	$1.03M	$1.11M	$1.22M
Stock-Based Compensation	$14.46M	$15.23M	$20.21M	$25.04M
Investing Cash Flow	-$109.25M	-$43.40M	$22.14M	-$148.03M
Financing Cash Flow	$25.23M	$85.66M	$126.55M	$245.26M
Net Change in Cash	-$159.17M	-$43.43M	$36.02M	-$13.74M

ORIC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$24.64M	$30.55M	$28.77M	$25.86M	$31.44M
Selling, General & Admin	$8.08M	$8.52M	$7.90M	$8.70M	$8.18M
Operating Expenses	$32.72M	$39.06M	$36.67M	$34.55M	$39.62M
Operating Income	-$32.72M	-$39.06M	-$36.67M	-$34.55M	-$39.62M
EBITDA	-$32.42M	-$38.75M	-$36.38M	-$34.23M	-$39.35M
Pretax Income	-$30.02M	-$36.35M	-$32.59M	-$30.50M	-$35.77M
Net Income	-$30.02M	-$36.35M	-$32.59M	-$30.50M	-$35.77M
Diluted EPS	-0.42	-0.47	-0.33	-0.30	-0.34
Diluted Shares	71.04M	78.13M	98.95M	102.59M	105.47M

ORIC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$49.33M	$75.86M	$49.67M	$45.67M	$56.40M
Current Assets	$211.43M	$291.12M	$295.59M	$288.47M	$290.23M
Total Assets	$242.86M	$346.86M	$431.19M	$408.89M	$436.76M
Current Liabilities	$17.62M	$18.05M	$20.18M	$20.42M	$17.77M
Total Debt	$3.21M	$3.27M	$3.30M	$3.33M	$3.30M
Total Liabilities	$23.12M	$22.86M	$24.27M	$24.53M	$21.20M
Retained Earnings	-$592.79M	-$629.15M	-$661.74M	-$692.24M	-$728.01M
Shareholders' Equity	$219.74M	$324.00M	$406.92M	$384.36M	$415.56M
Working Capital	$193.82M	$273.07M	$275.42M	$268.05M	$272.46M

ORIC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$32.53M	-$30.84M	-$25.11M	-$22.48M	-$32.44M
Capital Expenditure	-$387.00K	-$63.00K	-$35.00K	-$227.00K	-$2.00K
Free Cash Flow	-$32.92M	-$30.91M	-$25.15M	-$22.71M	-$32.44M
Depreciation & Amortisation	$302.00K	$310.00K	$288.00K	$320.00K	$270.00K
Stock-Based Compensation	$6.55M	$6.57M	$5.63M	$6.28M	$6.90M
Investing Cash Flow	$22.45M	-$76.93M	-$110.53M	$16.98M	-$17.98M
Financing Cash Flow	$11.00K	$134.30M	$109.45M	$1.50M	$61.14M
Net Change in Cash	-$10.07M	$26.53M	-$26.20M	-$4.00M	$10.73M

Market Snapshot

About

Oric Pharmaceuticals is a clinical-stage oncology biotechnology company focused on developing therapies to overcome drug resistance in cancer. The company advances precision medicines targeting cancer resistance mechanisms, including programs focused on hormone receptor-positive breast cancer and prostate cancer.